This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01296932
First received: February 15, 2011
Last updated: July 19, 2017
Last verified: July 2017
February 15, 2011
July 19, 2017
February 11, 2011
May 30, 2017   (Final data collection date for primary outcome measure)
  • Determination of the maximum tolerated dose of BI 836826 [ Time Frame: 12 months ]
  • Incidence of dose limiting toxicity (DLT) [ Time Frame: 12 months ]
Determination of the maximum tolerated dose of BI 836826 [ Time Frame: 12 months ]
Complete list of historical versions of study NCT01296932 on ClinicalTrials.gov Archive Site
  • Number of lymphocytes in the peripheral blood [ Time Frame: 12 months ]
  • Tumour size [ Time Frame: 12 months ]
  • Blood counts [ Time Frame: 12 months ]
  • Best overall response [ Time Frame: 12 months ]
  • Progression free survival [ Time Frame: 12 months ]
  • Failure free survival [ Time Frame: 12 months ]
  • Pharmacokinetic parameters [ Time Frame: 12 months ]
  • Incidence and intensity of adverse events graded according to CTCAE [ Time Frame: 12 months ]
  • Incidence of dose limiting toxicity (DLT) [ Time Frame: 12 months ]
  • Assessment of safety laboratory parameters [ Time Frame: 12 months ]
  • Number of lymphocytes in the peripheral blood [ Time Frame: 12 months ]
  • Tumour size [ Time Frame: 12 months ]
  • Blood counts [ Time Frame: 12 months ]
  • Best overall response [ Time Frame: 12 months ]
  • Progression free survival [ Time Frame: 12 months ]
  • Failure free survival [ Time Frame: 12 months ]
Not Provided
Not Provided
 
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia
Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial. The trial will examine whether monotherapy with BI 836826 is safe and tolerable at escalating dose levels.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: BI 836826
Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
Experimental: Patients with relapsed CLL
Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
Intervention: Drug: BI 836826
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
37
July 10, 2017
May 30, 2017   (Final data collection date for primary outcome measure)

Inclusion criteria:

  1. Diagnosis of relapsed or refractory chronic lymphocytic leukaemia.
  2. At least two prior treatment regimens for chronic lymphocytic leukaemia.
  3. At least one criterion for active disease as defined by the International Workshop on CLL.
  4. Absolute lymphocyte count lower than 200 x 10^9/l .
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2.
  6. Age 18 years or older.
  7. Written informed consent which is consistent with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines and local legislation.

Exclusion criteria:

  1. Treatment with anti CD 20 therapy within 4 weeks, or alemtuzumab within 8 weeks, or any cytotoxic antileukemia therapy within 2 weeks, Ibrutinib or Idelalisib within 1 week prior to the first administration of the trial drug.
  2. Prior allogeneic stem cell transplantation.
  3. Active autoimmune haemolytic anemia.
  4. Active autoimmune thrombocytopenia.
  5. Known transformation to an aggressive B-cell malignancy.
  6. Concurrent treatment with relevant doses of systemic glucocorticosteroids.
  7. Prior history of malignancy other than chronic lymphocytic leukaemia (exceptions to this rule are defined in the clinical trial protocol).
  8. Aspartate aminotransferase or alanine aminotransferase > 2.5 x upper limit of normal.
  9. Total bilirubin > 1.5 x upper limit of normal.
  10. Absolute Neutrophil Count < 1.000/µl.
  11. Platelets < 25.000/µL.
  12. Estimated Glomerular Filtration Rate <45 mL/min.
  13. Proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher.
  14. Significant concurrent disease.
  15. Any infectious disease requiring treatment at the time of enrolment or within the previous 2 weeks.
  16. Hepatitis B or C.
  17. Human Immunodeficiency Virus (HIV) infection.
  18. Cytomegalovirus (CMV) viremia.
  19. Women of childbearing potential not using a highly effective method of birth control during the trial until one year after the last dose.
  20. Pregnancy or breast feeding.
  21. Known or suspected active alcohol or drug abuse.
  22. Treatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial.
  23. Prior treatment with BI 836826.
  24. Patients unable to comply with the protocol
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   France,   Germany
United States
 
NCT01296932
1270.1
2010-021488-34 ( EudraCT Number )
Not Provided
Not Provided
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP